Effectiveness and durability of ready-to-use botulinum toxin A formulations (Relfydess and Alluzience) for treating moderate to severe frown lines: a randomized controlled clinical trial

Efficacy and durability of liquid formulations of botulinum toxin type A, Relabotulinumtoxin-A (Relfydess) and RTU Abobotulinumtoxin-A (Alluzience), in the treatment of moderate-to-severe dynamic glabellar lines: a randomized, controlled, triple-blind clinical study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-10tkjh3t

Enrollment

Registered

2026-04-26

Start date

2026-02-01

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial Muscles Skin Aging

Interventions

This study is designed as a randomized, controlled, two-arm, triple-blind clinical trial, in which participants, the injector, and the outcome assessor are all blinded to group allocation. A total of

Alluzience), while the comparator group (G2) will receive a single administration of relabotulinumtoxinA (Relfydess), both injected into the glabellar region. All procedures will be performed under st

Eligibility

Sex/Gender

Female

Age

25 Years to 50 Years

Inclusion criteria

Inclusion criteria: female patients aged between 25 and 50 years; presence of dynamic glabellar lines involving the procerus and corrugator muscles; no botulinum toxin injections within the last year for aesthetic or therapeutic purposes in any body region; moderate to severe glabellar lines according to the 5-point Merz scale; and no aesthetic procedures performed in the upper third of the face within the last year. 3. Moderate to severe glabellar lines according to the 5-point Merz scale; 4. No other aesthetic procedures performed in the upper third of the face within the last year.

Exclusion criteria

Exclusion criteria: receipt of tetanus or COVID-19 vaccination within the last three months prior to study initiation; presence of autoimmune diseases; pregnancy or breastfeeding; presence of neuromuscular disorders, such as myasthenia gravis or Lambert–Eaton syndrome; current use of medications affecting neuromuscular junctions; engagement in high-intensity physical exercise; and refusal or inability to sign the Informed Consent Form

Design outcomes

Primary

Measure	Time frame
It is expected that the efficacy and durability of RTU relabotulinumtoxin-A (Relfydess) will be superior to RTU abobotulinumtoxin-A (Alluzience) in improving the severity of glabellar lines	—

Secondary

Measure	Time frame
No secondary outcomes are expected	—

Countries

Contacts

Public ContactLucas Sousa Mendes

Centro Universitário Uningá

drlucassousamendes.cd@outlook.com47999551238

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: May 1, 2026